Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis

Table 2 Summary of reported cases with venous and arterial thrombotic events in pregnant women with confirmed COVID-19 infection

Case	Study number	Number requiring critical care	Number of maternal deaths	Type of arterial thrombotic events	Type of venous thrombotic events 1 = inferior vena cava 2 = pulmonary embolism 3 = DVT	Number symptomatic	Diagnosis of event made antenatally (1) or postnatally (2)	Number receiving thromboprophylaxis prior to VTE event	If thromboprophylaxis reported, what type and what dose?	D-dimer measurement (micrograms/ml normal = < 0.5)	Risk factors: PET = 1, smoker = 2, FHx VTE = 3, Age > 35 = 4, IVF = 5, twins = 6, parity > 3 = 7, BMI > 30 = 8
1	65	1	0	0	1		1	1	“therapeutic anticoagulation”	Not given	7
2	87	1	0	0^a	0		1	1	enoxaparin 40 mg subcutaneously daily. BMI 41.5	0.57–2.82	4,8
3	UKOSS (107)	1	1	Basilar artery thrombosis	2	1 “Deteriorating respiratory function”	2	1	Enoxaparin (prophylactic dose)	Not given	8,
4	141		1	0	2
5	159	1	0	0	0^b	0	1	1	Lovenox 40 mg daily	Not given	4,5

^a Arterial line required replacement multiple times due to thrombosis despite VTE prophylaxis”
^b Patient was undergoing dialysis via central venous line catheter. “Despite the thromboprophylaxis, the blood repeatedly coagulated in the dialysis machine. Thus, the patient was started on a continuous heparin drip”
¹Few papers specifically stated negative findings for coagulopathy or thrombosis. Cases were therefore considered negative for these events if it was stated that there were no complications during the observed clinical course, or if patients were stated to have recovered/be recovering, or discharged without mention of coagulopathy or thrombosis

ISSN: 1471-2393